Altamira reports breakthrough in cancer treatment

HAMILTON, Bermuda - Altamira Therapeutics Ltd. (NASDAQ:CYTO), a biopharmaceutical company, announced significant advancements in cancer treatment through the use of its novel SemaPhore™ nanoparticle technology, as detailed in a recent publication in Nature Immunology.

The study, led by researchers at Washington University School of Medicine, demonstrated that Zbtb46 mRNA nanoparticles, when combined with immune checkpoint inhibitors, notably anti-PD1 therapies, could lead to long-term remission of solid tumors in animal models.

The research highlighted the crucial role of the Zbtb46 gene in controlling tumor growth, suggesting that increasing its expression could counteract the immunosuppressive environment that often hinders effective cancer treatment. By delivering Zbtb46 mRNA encapsulated in SemaPhore™ nanoparticles, the treatment induced a significant reduction in tumor growth, with the potential to improve outcomes for a broader range of patients who are currently unresponsive to anti-PD1 therapies like Keytruda and Opdivo.

Altamira's Chief Scientific Adviser, Dr. Samuel Wickline, noted the impressive results from the study, emphasizing the potential of the SemaPhore platform to deliver mRNA therapeutics to tissues beyond the liver. The combination therapy not only controlled tumor growth but also promoted immunological memory, suggesting durable protection against cancer recurrence.

The SemaPhore platform is designed to facilitate the safe and efficient delivery of mRNA into target cells, with the ability to bypass hepatic clearance and reach non-hepatic tissues. This versatility has been demonstrated in multiple disease models.

Altamira, headquartered in Hamilton, Bermuda, with operations in Basel, Switzerland, is focused on developing peptide-based nanoparticle technologies for RNA delivery. The company is also advancing preclinical development of siRNA programs targeting KRAS-driven cancer and rheumatoid arthritis.

This news is based on a press release statement and the findings published in Nature Immunology. Altamira has cautioned that forward-looking statements involve risks and uncertainties, and actual results may differ materially from those projected. The company does not assume any obligation to update these statements in light of new information or future events.

In other recent news, Altamira Therapeutics has made significant strides in various areas of its research and development. The biopharmaceutical company has announced promising results from an animal study on the treatment of abdominal aortic aneurysm (AAA) using its SemaPhore nanoparticles. The company also highlighted the potential of its AM-125, a nasal spray formulation of betahistine, in treating residual dizziness in patients with benign paroxysmal positional vertigo, based on promising results from a Phase 2 clinical trial.

Altamira has made considerable advancements in the stability of RNA nanoparticles essential for the handling and transport of RNA formulations. The company's OligoPhore nanoparticles now remain stable in liquid form at 4°C for at least three weeks. Altamira's Bentrio nasal spray has shown positive results in a clinical trial for seasonal allergic rhinitis, demonstrating a significant reduction in symptoms.

The company has also reported progress in strategic repositioning, focusing on RNA delivery technologies and the advancement of its proprietary drug development programs. Altamira has filed a provisional patent application for a new RNA-based therapeutic targeting inflammatory and cancer-related pathways. The company reported a reduction in operating expenses and an improved financial position. These are some of the recent developments at Altamira Therapeutics.

InvestingPro Insights

Amidst the promising research advancements by Altamira Therapeutics Ltd. (NASDAQ:CYTO), the company's financial health and market performance provide additional context for investors. Altamira holds a stronger cash position than debt on its balance sheet, which could offer some financial stability as it continues to invest in its innovative SemaPhore™ nanoparticle technology. Moreover, the stock is trading at a low Price / Book multiple of 0.36 as of the last twelve months ending Q4 2023, indicating that it might be undervalued relative to its assets.

InvestingPro data reveals a market capitalization of $2.72M, reflecting the company's current valuation in the market. However, investors should note that Altamira has been operating at a loss, with an operating income of approximately -$7.03M over the same period. Moreover, the company's stock price has experienced significant volatility, with a 10.87% return over the last week, yet a substantial decline of 85.9% over the past year. This volatility is echoed in the InvestingPro Tips, which highlight Altamira's stock price movements as quite volatile.

For investors seeking further insights, there are additional InvestingPro Tips available on Altamira, including analysts' expectations and historical stock performance. A deeper dive into these tips could offer a more comprehensive understanding of the company's investment potential.

Altamira's next earnings date is set for September 12, 2024, which will likely provide further insights into the company's financial trajectory and the progress of its clinical programs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.